OSL:GENT - Euronext Oslo - NO0010748866 - Common Stock - Currency: NOK
OSL:GENT (3/7/2025, 7:00:00 PM)
46.8
-0.8 (-1.68%)
The current stock price of GENT.OL is 46.8 NOK. In the past month the price decreased by -3.7%. In the past year, price increased by 21.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EL.PA | ESSILORLUXOTTICA | 53.13 | 124.44B | ||
ESL.DE | ESSILORLUXOTTICA | 53.09 | 124.35B | ||
1EL.MI | ESSILORLUXOTTICA | 52.97 | 124.08B | ||
CBHD.DE | COLOPLAST-B | 33.98 | 21.00B | ||
GBT.PA | GUERBET | 10.23 | 341.28M | ||
ALCJ.PA | CROSSJECT | N/A | 91.07M | ||
PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 89.03M | ||
AFME.PA | AFFLUENT MEDICAL SA | N/A | 55.09M | ||
SVS.MI | SVAS BIOSANA SPA | 7.25 | 41.44M | ||
IVN.MI | IVISION TECH SPA | N/A | 16.85M |
Gentian Diagnostics ASA is a medical diagnostics company, which engages in the design, development, and manufacture of biochemical reagents and materials for use in medical diagnostics and research. The company is headquartered in Moss, Ostfold and currently employs 58 full-time employees. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
GENTIAN DIAGNOSTICS ASA
Bjornasveien 5
Moss OSTFOLD NO
Employees: 58
Company Website: https://www.gentian.com/
Investor Relations: http://www.gentian.com/investor-relation
Phone: 4799339905
The current stock price of GENT.OL is 46.8 NOK. The price decreased by -1.68% in the last trading session.
The exchange symbol of GENTIAN DIAGNOSTICS ASA is GENT and it is listed on the Euronext Oslo exchange.
GENT.OL stock is listed on the Euronext Oslo exchange.
7 analysts have analysed GENT.OL and the average price target is 68.34 NOK. This implies a price increase of 46.03% is expected in the next year compared to the current price of 46.8. Check the GENTIAN DIAGNOSTICS ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENTIAN DIAGNOSTICS ASA (GENT.OL) has a market capitalization of 721.66M NOK. This makes GENT.OL a Small Cap stock.
GENTIAN DIAGNOSTICS ASA (GENT.OL) currently has 58 employees.
GENTIAN DIAGNOSTICS ASA (GENT.OL) has a support level at 46.79 and a resistance level at 48.48. Check the full technical report for a detailed analysis of GENT.OL support and resistance levels.
The Revenue of GENTIAN DIAGNOSTICS ASA (GENT.OL) is expected to grow by 33.11% in the next year. Check the estimates tab for more information on the GENT.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GENT.OL does not pay a dividend.
The PE ratio for GENTIAN DIAGNOSTICS ASA (GENT.OL) is 16.31. This is based on the reported non-GAAP earnings per share of 2.87 and the current share price of 46.8 NOK. Check the full fundamental report for a full analysis of the valuation metrics for GENT.OL.
ChartMill assigns a technical rating of 6 / 10 to GENT.OL. When comparing the yearly performance of all stocks, GENT.OL is one of the better performing stocks in the market, outperforming 79.29% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL. GENT.OL has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months GENT.OL reported a non-GAAP Earnings per Share(EPS) of 2.87. The EPS increased by 520.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 29.78% | ||
ROA | 19.72% | ||
ROE | 23.34% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 86% to GENT.OL. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 76.24% and a revenue growth 33.11% for GENT.OL